Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients

Trial Profile

Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Quercetin (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAT IQ
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 26 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top